Navigation Links
Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
Date:6/19/2008

SYDNEY, Australia, June 19 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that the company and the U.S. Food and Drug Administration (FDA) have reached agreement on the phase 3 registration trial of Bronchitol for bronchiectasis via the Special Protocol Assessment process.

The SPA process allows for FDA evaluation of a clinical trial protocol intended to form the primary basis of an efficacy claim in support of a New Drug Application, and provides an agreement that the study design, including trial size, clinical endpoints and/or data analyses are acceptable to the FDA.

Pharmaxis previously agreed on the trial design with the European regulatory agency (EMEA). This trial will therefore form the basis of a marketing application in both the U.S. and Europe.

The phase 3 trial has been designed in collaboration with internationally renowned experts in the field of bronchiectasis and will be a randomized, placebo controlled, double-blind investigation of Bronchitol twice daily in approximately 350 adults with bronchiectasis. Participants will be treated for 52 weeks and the primary endpoints are reduction in frequency of exacerbations and improvement in quality of life. Secondary endpoints include time to first exacerbation and duration of exacerbation. Additional secondary endpoints are antibiotic use, sputum volume, exercise tolerance and lung function measurements. The trial includes health economic analysis and will be conducted in centers across Europe and the U.S.

This trial is the second Phase III study to be undertaken for Bronchitol in bronchiectasis and follows the completion of a successful shorter trial reported last year.

Pharmaxis CEO, Alan Robertson, said the company was pleased to have concluded its discussions with the FDA and the EMEA.

''We believe this phase 3 trial design will allow us to thoroughly demonstrate the clinical benefits of Bronchitol in a patient populat
'/>"/>

SOURCE Pharmaxis Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmaxis Establishes Named Patient Program for Bronchitol
2. Pharmaxis Long-Term Safety Study of Bronchitol Completes
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
5. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
6. Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
9. Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist
10. Specialized Genasense(R) Clinical Trials Featured at AACR Meeting
11. Associated Foot & Ankle Specialists Enrolling Patients With Chronic Diabetic Foot Ulcers for MATRIX Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
(Date:1/14/2014)... LEESBURG, Va. , Jan. 14, 2014 Animal Emergency Critical ... in Leesburg, Virginia is the first in ... hyperbaric oxygen chamber. Dr. Susan M. Barnes ... years. Dr. Barnes and husband, Dr. Cole Taylor , are ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... N.J., Nov. 4, 2010 The Hyacinth AIDS ... organization serving over 15,000 people annually, announced today that ... fight against HIV/AIDS in the local community at its ... 13th.   The Hyacinth AIDS Foundation will ...
... 2010 Interventional Spine®, Inc. today announced that ... Patent No. 7,824,429, entitled Method and Apparatus for ... provide key patent protection for the Company,s percutaneous ... under the PERPOS® PLS System name and including ...
Cached Medicine Technology:Hyacinth AIDS Foundation to Honor Local Leaders in the Fight Against HIV/AIDS and Celebrate 25 Years of Service to the HIV/AIDS Community 2Interventional Spine®, Inc. Announces Issuance of Key Patents for the PERPOS® PLS System 2
(Date:4/24/2014)... The University of Manchester have identified a way to ... open to treatment. , The study published today in ... the development of drugs to target cells that have ... the discovery whilst exploring the possible mechanisms behind resistance ... breast and colon cancer. , Dr Andrew Gilmore, who ...
(Date:4/24/2014)... April 24, 2014 ,Take me out to ... slices and kale chips. The more likely culprits include ... , Unfortunately for children who play youth baseball, ... contributing to weight problems, according to researchers at Wake ... current online edition of Childhood Obesity , found ...
(Date:4/24/2014)... and the relevance of palliation in advanced cancer ... controlled trials (RCTs). This is the result of ... and Efficiency in Health Care (IQWiG), which has ... with external experts, IQWiG analysed studies on four ... melanoma, and pancreatic cancer. For this purpose, the ...
(Date:4/24/2014)... has been awarded one of 30 grants from the ... Academic Participating Site in its new National Clinical ... select groups of investigators charged with distributing resources in ... NCTN grant system reflects recommendations from a 2010 ... achieve four goals:, Faster design, launch, and ...
(Date:4/23/2014)... (MGH) investigators may lead to greater availability and acceptability ... use of fecal material from healthy donors to ... ( C. difficile ) bacteria. In their ... Infectious Diseases , the researchers report that use of ... was as successful in curing recurrent C. difficile ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Take the bat, leave the candy 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3
... ... Deepak Chopra and Dr. David Simon have expanded upon their extensive line of ... body. Enjoy and share the benefits of the age-old wisdom and timeless healing ... Guide and find the perfect gift that shows you care and helps transform ...
... nearly four billion people living in 47 different countries, and ... health issues. But when they come to the United States, ... Health researchers say this makes it difficult to learn ... one of the leading killers of Asian-Americans. "There is ...
... 2009) Findings from a new retrospective cohort ... Annual Scientific meeting in San Diego indicate that patients ... thiopurine class of medications to treat IBD, may be ... Dr. Millie Long, of the University of North Carolina, ...
... In two new studies, presented at the American College ... Diego, researchers explored the connection between high stress, high ... performed by the United States Navy and the State ... term effects of infectious gastroenteritis (IGE) among active duty ...
... , ARLINGTON, Va., Oct. 29 The American Chemistry Council ... EPA and published online yesterday in the journal Toxicological Sciences. ... and ethinyl estradiol (EE2)in utero in a wide range of doses ... be attributed to Steven G. Hentges, Ph.D., ACC,s Polycarbonate/BPA ...
... Consumer Watchdog sent the following letter to Congressional leaders ... Governor Arnold Schwarzenegger in which he incorrectly cited California,s ... as a successful cost containment tool. Consumer Watchdog ... Washington, D.C. The Governor,s October 27, 2009 letter ...
Cached Medicine News:Health News:The Chopra Center for Wellbeing Online Holiday Gift Guide -- Gifts that Make a Difference 2Health News:The Chopra Center for Wellbeing Online Holiday Gift Guide -- Gifts that Make a Difference 3Health News:1 disease, not 1 demographic 2Health News:1 disease, not 1 demographic 3Health News:Study reveals possible link between IBD therapy and skin cancer 2Health News:New studies explore connection between high stress jobs and GI disorders 2Health News:New studies explore connection between high stress jobs and GI disorders 3Health News:New EPA Rodent Study Finds No Low-Dose BPA Effects on Reproductive Function or Behavior 2Health News:Consumer Group Responds to Governor Schwarzenegger's Incorrect Claims About the Impact of Medical Malpractice Caps 2Health News:Consumer Group Responds to Governor Schwarzenegger's Incorrect Claims About the Impact of Medical Malpractice Caps 3
... Original Knee Brace gives fracture treatment patients ... control, this brace features the the Bledsoe ... from 0-120, and positively locks at any ... eccentric cam slots, the Bledsoe Multi-Centric Hinge ...
The Bledsoe Post-Op Knee Brace is designed to provide maximum protection without sacrificing comfort and quick, easy application....
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
Medicine Products: